Sara Tolaney

Sara Tolaney is a breast oncologist who has led clinical investigations into immunotherapy combinations in breast cancer, including pembrolizumab plus chemotherapy in KEYNOTE-522 and studies combining checkpoint inhibitors with ADCs, PARP inhibitors, and CDK4/6 inhibitors. Her research has explored the immunologic basis for combination activity in TNBC and HER2-positive breast cancer, and she has been a primary investigator on multiple trials testing novel IO+targeted therapy combinations. She co-chairs the ASCO Cancer Research Committee and serves on multiple guideline panels.